JUDY WOODRUFF: As the COVID summer surge climbs, before there is a cure, Miles O'Brien explores
the push to find ways to treat the virus.
It's part of our Leading Edge series on science and innovation.
And a note: Some of the video Miles used here was shot as part of an earlier collaboration
with PBS' "Frontline."
MILES O'BRIEN: Emergency room physician Ryan Padgett is back home with his family, on the
mend after a near-death experience, a Hail Mary pass, and a stunning victory over COVID-19.
It all began in late February, when he and the team at Merchant Logo
EvergreenHealth Kirkland began treating some very sick nursing home residents with the
symptoms of viral pneumonia.
DR. RYAN PADGETT, EvergreenHealth Medical Center Kirkland: You're used to dealing with
patients with illness, but to realize that you're going to potentially have 60 patients
from one place with this novel illness was kind of scary
MILES O'BRIEN: Still, with only a handful of sick days in 19 years on the job, Dr. Padgett
wasn't too concerned about his own health. In fact, he was the picture of it.
A starting offensive lineman for Northwestern University in the 1996 Rose Bowl, he has always
stayed in great shape. Then the telltale symptoms of COVID-19 came rushing through his body's
defensive line.
DR. RYAN PADGETT: And I was like, wow, something is different here.
And, pretty quickly, I came to kind of think, timing wise, that I was probably infected.
They call it the beast, and you realize why. It's like getting hit by a truck.
MILES O'BRIEN: Things went downhill fast. He ended up in the intensive care unit at
Seattle's Swedish Medical Center on a ventilator and a heart lung machine.
Sure, the virus had done plenty of damage, but inside his body, something else was at
play. Dr. Padgett's immune system had mounted a counteroffensive that had run amok. This
overreaction is called a cytokine storm.
DR. RYAN PADGETT: My immune system had caught a wildfire. My body overreacted and was putting
me into kidney failure, respiratory failure. My heart and even my liver started going downhill.
MILES O'BRIEN: It was not a surprise. There were numerous reports from China of COVID
patients who succumbed to a cytokine storm.
A similar thing sometimes happens to cancer patients receiving immunotherapy. So, the
medical team reached out to the oncology department.
Dr. Krish Patel.
DR. KRISH PATEL, Swedish Medical Center: We were all really learning day to day how to
try to manage this illness, and I think that's where kind of borrowing from other disease
processes or other specialties seemed to make sense.
MILES O'BRIEN: He recommended an antibody called tocilizumab. In addition to helping
cancer patients, it is used to treat people with rheumatoid arthritis as well.
Doctors in China had some success with it, so the team here saw no reason not to try
it on Ryan Padgett. Within days, they had weaned him off the machines.
DR. KRISH PATEL: We were very encouraged by what we saw in his experience, since that
time have had -- developed continued experience with the medicine.
MILES O'BRIEN: Dr. Patel says the team at Swedish has now treated more than 65 COVID
patients with tocilizumab, with encouraging results.
He is participating in a big randomized study, results due later this summer.
But Ryan Padgett needs no convincing.
DR. RYAN PADGETT: It saved my life.
MILES O'BRIEN: You think?
DR. RYAN PADGETT: Absolutely. This isn't the time for a yearlong randomized control trial.
This is a time of, put your finger where it's bleeding and hold it there, and let's hope
it stops.
MILES O'BRIEN: Understandable in a pandemic, but it can often lead to false hope.
DEREK LOWE, "In the Pipeline": People want hope, but false hope is not just neutral.
False hope is worse than no hope at all.
MILES O'BRIEN: Chemist Derek Lowe has done early stage drug discovery for 30 years. He
also writes the well-respected blog "In the Pipeline."
People are scared and looking for a silver bullet.
DEREK LOWE: They sure are. And I don't blame them for a minute.
And we haven't had a situation like this. People are used to saying, OK, I have got
this disease. Where's the drug? I guess everyone is starting to learn a little bit more about
what drug discovery is like.
MILES O'BRIEN: We are all learning the hard way.
DONALD TRUMP, President of the United States: And a lot of good things have come out about
the hydroxy. A lot of good things have come out.
MILES O'BRIEN: President Trump frequently promoted the antimalarial drug hydroxychloroquine
as a COVID-19 therapeutic before there was scientific data to support the claims.
When that data came in, it showed hydroxychloroquine offers no benefit, but also great harm, causing
potentially fatal heart arrhythmias in some patients.
On June 15, the Food and Drug Administration revoked the emergency use authorization for
hydroxychloroquine as a COVID-19 treatment.
Dr. George Diaz treated the first U.S. COVID-19 patient at Providence Regional Medical Center
in Everett. He was failing fast, when Dr. Diaz got permission from the FDA and the patient
to try the antiviral drug remdesivir.
DR. GEORGE DIAZ, Providence Regional Hospital: He was still having very high fevers and still
was requiring oxygen the day that we gave it to him.
By the next day, his fevers resolved, and they stayed gone. And he was able to come
off of oxygen one day after receiving treatment. So -- and he felt much better. He felt like
he had started beating the virus.
MILES O'BRIEN: Dr. Diaz is participating in a big randomized study of remdesivir, and,
in the meantime, continues to see lots of encouraging signs among the patients he treats.
WOMAN: I sent two people home today.
DR. GEORGE DIAZ: Oh, that's fantastic.
WOMAN: Yes.
MILES O'BRIEN: A separate study released at the end of May shows remdesivir slightly reduces
the length of hospital stays for COVID-19 patients.
DEREK LOWE: So, that tells you about where the drug is, helpful, but not a cure, because
there's no way that one single drug can shut down a viral infection. That's one thing that
we have sort of proven over the years.
MILES O'BRIEN: Doctors on the front lines all over the world have tried hundreds of
drugs for off-label use on COVID patients.
The most promising? A steroid called dexamethasone. One study shows it reduces the mortality rate
for COVID patients on ventilators. But perhaps the most proven way to beat back a virus is
found in the blood of the survivors.
After all, the antibodies it contains have proven their mettle by defeating the virus.
But so-called convalescent plasma has limits. One survivor may only be able to help no more
than three others.
The solution to that may lie in immune cells which are cloned and grown in large batches.
They produce so called monoclonal antibodies, and scientists are now identifying the most
effective of them.
Dr. Robert Garry is a professor of microbiology and immunology at Tulane Medical School.
DR. ROBERT GARRY, Tulane University School of Medicine: These have worked very well IN
other serious diseases, like the Ebola virus. So, I'm waiting for the SARS-CoV-2 human monoclonal
antibodies. I think that those are very likely to have a major impact on the course of this
illness.
MILES O'BRIEN: Monoclonal antibodies are like a temporary vaccine for those who are sick,
their families, and for health care workers.
And while it likely won't take as long to bring them to the market as a vaccine, scaling
up production to meet global demand will take time, and maybe more patience than we have.
For the "PBS NewsHour," I'm Miles O'Brien in Seattle.